NEW YORK, Oct. 1 – Orchid BioSciences said Monday it had sold its SNPstream system for SNP scoring to Tepnel Life Sciences and made an equity investment in the Manchester, UK-based company.

Under the terms of the deal, Tepnel will also gain access to Orchid’s SNP databases and biochemistry and software kits. In exchange Orchid has acquired the option to evaluate some of Tepnel’s discoveries for possible commercialization.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.